Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167)
8.02
-0.18 (-2.20%)
Apr 17, 2026, 1:04 PM HKT
Jacobio Pharmaceuticals Group Employees
Jacobio Pharmaceuticals Group had 196 employees as of December 31, 2025. The number of employees decreased by 61 or -23.74% compared to the previous year.
Employees
196
Change
-61
Growth
-23.74%
Revenue / Employee
303.89K HKD
Profits / Employee
-828.82K HKD
Market Cap
6.44B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 196 | -61 | -23.74% |
| Jun 30, 2025 | 211 | - | - |
| Dec 31, 2024 | 257 | -44 | -14.62% |
| Dec 31, 2023 | 301 | -2 | -0.66% |
| Dec 31, 2022 | 303 | 41 | 15.65% |
| Dec 31, 2021 | 262 | 85 | 48.02% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Viva Biotech Holdings | 2,169 |
| Shanghai Haohai Biological Technology | 2,156 |
| CK Life Sciences Int'l., (Holdings) | 1,920 |
| Shandong Boan Biotechnology | 714 |
| Ocumension Therapeutics | 505 |
| Qyuns Therapeutics | 337 |
| Abbisko Cayman | 226 |
| Beijing Luzhu Biotechnology | 205 |
Jacobio Pharmaceuticals Group News
- 4 months ago - Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73 - PRNewsWire
- 6 months ago - Jacobio Pharma Announces Strategic Partnership with Oceanpine Capital to Focus on Core Oncology Pipeline - PRNewsWire
- 8 months ago - Jacobio Pharma Announces 2025 Interim Results - PRNewsWire
- 10 months ago - Jacobio's IND for Phase I/II Clinical Trial of BET Inhibitor JAB-8263 in Autoimmune Diseases has been Accepted - PRNewsWire